Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer.

Abacioglu U. , Yumuk P., Caglar H., Sengoz M. , Turhal N.

BMC cancer, cilt.5, ss.71, 2005 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1186/1471-2407-5-71
  • Dergi Adı: BMC cancer
  • Sayfa Sayıları: ss.71


Background: Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC.